glucagon like peptide 1 glp 1 agonists Glucagon-like 1(GLP-1) receptor in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist Cardiovascular effects of Glucagon-like peptide
Description
Our findings strongly suggest the answer is yes. Primes recent real-world study found 63% of high-potency GLP-1 (Wegovy or Zepbound) users who started treatment in Q1 2024 are still taking their medication after a year
We and others have shown that GLP-1 drugs reduce risks of many substance use and addiction disorders.
Introduction The global obesity market is entering a new phase
To evaluate changes in time-in-therapeutic INR range (TTR) among warfarin patients initiated on GLP-1 RA therapy
Random-effects models were applied, and sensitivity analyses examined result stability
Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand
